plec (Santa Cruz Biotechnology)

Santa Cruz Biotechnology is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Santa Cruz Biotechnology plec

Figure 2. Representative images of plakin expression in benign and cancerous solid ovarian tumours evaluated by immunohistochemistry. Representative images of protein expression using immuno- histochemistry in benign ovarian tissue, borderline, Type I and Type II tumours. <t>(a)</t> <t>PPL,</t> (b) <t>PLEC,</t> (c) EVPL immunostaining, and (d) IHC negative control image using secondary-only anti-mouse HRP-labelled DAB staining. Images were taken using a Leica DLMB microscope with attached Leica DFC450C camera and LAS software 4.8.0, ×40 magnification (D ×20 magnification) or from Aperio Imagescope software 12.3.

Plec, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 72 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plec/Plectin+Antibody/pm39682273-71-35-46
Average 93 stars, based on 72 article reviews

plec - by Bioz Stars, 2026-10

93/100 stars

Images

1) Product Images from "Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets."

Journal: Cancers

doi: 10.3390/cancers16234087

Figure Legend Snippet: Figure 2. Representative images of plakin expression in benign and cancerous solid ovarian tumours evaluated by immunohistochemistry. Representative images of protein expression using immuno- histochemistry in benign ovarian tissue, borderline, Type I and Type II tumours. (a) PPL, (b) PLEC, (c) EVPL immunostaining, and (d) IHC negative control image using secondary-only anti-mouse HRP-labelled DAB staining. Images were taken using a Leica DLMB microscope with attached Leica DFC450C camera and LAS software 4.8.0, ×40 magnification (D ×20 magnification) or from Aperio Imagescope software 12.3.

Techniques Used: Expressing, Immunohistochemistry, Immunostaining, Negative Control, Staining, Microscopy, Software

Figure 3. Quantitative analysis of plakins staining in benign ovarian tissues and serous ovarian tumours. Quantification of plakin protein expression staining using DAB immunohistochemistry. Positivity output from Aperio was normalized to background (non-epithelial cell) staining. Quantifi- cation of IHC staining: (a) PPL, (b) PLEC and (c) EVPL for each of cases sorted by WHO tumour Type, cases sorted by FIGO surgical stage, (blue data points represent WHO Type I cases) and cases sorted by Silverberg–Shimizu tumour grade. For PPL expression at a), statistical significance measured by one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.005. For PLEC at (b), statistical significance measured by one-way ANOVA, * p < 0.05. For EVPL at (c), statistical significance was measured by one-way ANOVA; no significance was determined between the groups.

Figure Legend Snippet: Figure 3. Quantitative analysis of plakins staining in benign ovarian tissues and serous ovarian tumours. Quantification of plakin protein expression staining using DAB immunohistochemistry. Positivity output from Aperio was normalized to background (non-epithelial cell) staining. Quantifi- cation of IHC staining: (a) PPL, (b) PLEC and (c) EVPL for each of cases sorted by WHO tumour Type, cases sorted by FIGO surgical stage, (blue data points represent WHO Type I cases) and cases sorted by Silverberg–Shimizu tumour grade. For PPL expression at a), statistical significance measured by one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.005. For PLEC at (b), statistical significance measured by one-way ANOVA, * p < 0.05. For EVPL at (c), statistical significance was measured by one-way ANOVA; no significance was determined between the groups.

Techniques Used: Staining, Expressing, Immunohistochemistry

Figure 7. Correlation of PLEC and PPL with EMT markers in WHO Type II primary tumour samples. Pearson correlation analysis of PLEC and PPL staining with EMT marker expression in Type II tumours from IHC staining. Top row: (a) PLEC vs. VIM, (b) PLEC vs. ECAD * p < 0.05, (c) PLEC vs. NCAD, (d) high PLEC (cases above mean PLEC expression) vs. NCAD * p < 0.05. Bottom row: (e) PPL vs. VIM, (f) PPL vs. ECAD, (g) PPL vs. NCAD, (h) high PPL (cases above mean PPL expression) vs. NCAD * p < 0.05.

Figure Legend Snippet: Figure 7. Correlation of PLEC and PPL with EMT markers in WHO Type II primary tumour samples. Pearson correlation analysis of PLEC and PPL staining with EMT marker expression in Type II tumours from IHC staining. Top row: (a) PLEC vs. VIM, (b) PLEC vs. ECAD * p < 0.05, (c) PLEC vs. NCAD, (d) high PLEC (cases above mean PLEC expression) vs. NCAD * p < 0.05. Bottom row: (e) PPL vs. VIM, (f) PPL vs. ECAD, (g) PPL vs. NCAD, (h) high PPL (cases above mean PPL expression) vs. NCAD * p < 0.05.

Techniques Used: Staining, Marker, Expressing, Immunohistochemistry

Figure 17. Kaplan–Meier analysis of overall and progression-free survival of patients in relation to mRNA expression of plakins. Cases analysed using the Kaplan–Meier Plotter website, dataset titled Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011) [49], with these conditions: WHO Type II serous ovarian cancer with p53 mutations, all treatment Types, and auto-threshold selection of high versus low expression. (a) PPL mRNA expression in relation to overall survival, (b) PPL mRNA expression in relation to progression-free survival, (c) PLEC mRNA expression in relation to overall survival, (d) PLEC mRNA expression in relation to progression-free survival, (e) EVPL mRNA expression in relation to overall survival, (f) EVPL mRNA expression in relation to progression- free survival. Sample numbers: n = 418 for OS, n = 398 for PFS, samples without relevant data were omitted.

Figure Legend Snippet: Figure 17. Kaplan–Meier analysis of overall and progression-free survival of patients in relation to mRNA expression of plakins. Cases analysed using the Kaplan–Meier Plotter website, dataset titled Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011) [49], with these conditions: WHO Type II serous ovarian cancer with p53 mutations, all treatment Types, and auto-threshold selection of high versus low expression. (a) PPL mRNA expression in relation to overall survival, (b) PPL mRNA expression in relation to progression-free survival, (c) PLEC mRNA expression in relation to overall survival, (d) PLEC mRNA expression in relation to progression-free survival, (e) EVPL mRNA expression in relation to overall survival, (f) EVPL mRNA expression in relation to progression- free survival. Sample numbers: n = 418 for OS, n = 398 for PFS, samples without relevant data were omitted.

Techniques Used: Expressing, Selection

Figure 19. Overall survival in relation to high and low expression of PPL (a), PLEC (b), and EVPL (c) in RWH cases (WHO Type II only). Data analysis and survival graphs produced with GraphPad Prism 10.2.0 software of the protein expression and survival data of the WHO Type II cases presented in Figures 1–7. Cases separated by level of plakin protein expression, high—above mean identified in Figure 2, low—below mean in Figure 3. No significant difference was found using Mantel–Cox (log-rank) test.

Figure Legend Snippet: Figure 19. Overall survival in relation to high and low expression of PPL (a), PLEC (b), and EVPL (c) in RWH cases (WHO Type II only). Data analysis and survival graphs produced with GraphPad Prism 10.2.0 software of the protein expression and survival data of the WHO Type II cases presented in Figures 1–7. Cases separated by level of plakin protein expression, high—above mean identified in Figure 2, low—below mean in Figure 3. No significant difference was found using Mantel–Cox (log-rank) test.

Techniques Used: Expressing, Produced, Software

Plasmid Preparation:

Article Title: Autophagosome–lysosome fusion is facilitated by plectin-stabilized actin and keratin 8 during macroautophagic process
Article Snippet: The pBABE-puro mCherry plasmid was purchased from Addgene (22,418), which was originally oriented by Jayanta Debnath (University of California at San Francisco, USA). .. Plasmid DNAs (pSELECT-GFP-LC3B [psetz-gfplc3b] and pUNO1-hKRT8, coding for Homo sapiens (Hs)/human KRT8 [puno1-hkrt8]) were purchased from InvivoGen. siRNAs targeting KRT8 (sc-35156), PP2A (sc-44033) , PLEC (sc-29453), and RAB11FIP2 (sc-90683) were purchased from Santa Cruz Biotechnology. .. LysoTracker Red DND-99 (L7528), 4′,6-diamidino-2-phenylindole (DAPI; D1306), and Lipofectamine 3000 (L3000015) were purchased from Invitrogen Life Technologies.

Staining:

Article Title: Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial–Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets
Article Snippet: The slides were dewaxed and rehydrated in a Ventana Benchmark Ultra automated IHC stainer (Oro Valley, AZ, USA). .. The staining process included antigen retrieval at pH 8.5, blocking of endogenous peroxidase activity, and incubating the tissue in primary antibody for 60 min. Each primary mouse anti-human antibody against PPL (G-1:sc-365530), EVPL (F-4:sc-137033), and PLEC (10F6:sc-33649) was used at a 1:100 dilution, was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). .. This was followed by the Optiview HQ universal linker amplification step, treatment with horseradish peroxidase, and detection by DAB (3,3′-Diaminobenzidine).

Article Title: Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets.
Article Snippet: The slides were dewaxed and rehydrated in a Ventana Benchmark Ultra automated IHC stainer (Oro Valley, AZ, USA). .. The staining process included antigen retrieval at pH 8.5, blocking of endogenous peroxidase activity, and incubating the tissue in primary antibody for 60 min. Each primary mouse anti-human antibody against PPL (G-1:sc-365530), EVPL (F-4:sc-137033), and PLEC (10F6:sc-33649) was used at a 1:100 dilution, was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). .. This was followed by the Optiview HQ universal linker amplification step, treatment with horseradish peroxidase, and detection by DAB (3,3′-Diaminobenzidine).

Blocking Assay:

Activity Assay:

other:

Article Title: KRT8 (keratin 8) attenuates necrotic cell death by facilitating mitochondrial fission-mediated mitophagy through interaction with PLEC (plectin).
Article Snippet: Dysregulation of mitochondrial homeostasis and accumulation of damaged mitochondria cause degenerative diseases such as age-related macular degeneration (AMD).. We studied the effects of the intermediate cytofilament KRT8 (keratin 8) on mitochondrial homeostasis in relation to the morphology and function of mitochondria in retinal pigment epithelial cells under oxidative stress.. When the mitochondria were damaged owing to oxidative stress, the damaged mitochondria were readily disposed of via mitophagy following mitochondrial fission.

Article Title: Autophagosome-lysosome fusion is facilitated by plectin-stabilized actin and keratin 8 during macroautophagic process.
Article Snippet: Autophagy is a lysosome-mediated degradative process that removes damaged proteins and organelles, during which autophagosome–lysosome fusion is a key step of the autophagic flux.. Based on our observation that intermediate cytofilament keratin 8 (KRT8) enhances autophagic clearance in cells under oxidative stress condition, we investigated whether KRT8 supports the cytoplasmic architectural networks to facilitate the vesicular fusion entailing trafficking onto filamentous tracks.. We found that KRT8 interacts with actin filaments via the cytolinker, plectin (PLEC) during trafficking of autophagosome.

Review